I

t’s been 61 days since the one and only oral argument in the CRISPR patent case. Where’s the decision?

Investors, lawyers, patent agents, biotech executives, and scientists have been anxiously waiting for the Patent Trial and Appeal Board to decide whether foundational CRISPR-Cas9 patents awarded to the Broad Institute of Harvard and MIT beginning in 2014 “interfered” with a patent application filed in 2012 by the University of California. Based on the time it usually takes PTAB to hand down a decision, this one should arrive “any day now,” said Jacob Sherkow of New York Law School, an expert on intellectual property law.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X